𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer

✍ Scribed by Bai Zhao; Tiemin Sun; Fanjuan Meng; Aibing Qu; Chunling Li; Hui Shen; Yu Jin; Wenxin Li


Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
678 KB
Volume
137
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Early lung cancer as a potential target
✍ Myron R. Melamed; Betty J. Flehinger πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 698 KB

Carcinoma of the lung is the most common cause of death from cancer in the United States. In considering lung cancer for possible chemoprevention trials, we have analyzed the data collected by the collaborative NCI program on early lung cancer. The data indicate that at least 12 years of study of 80

Chemopreventive potential of thiol conju
✍ Fung-Lung Chung; Ding Jiao; C. Clifford Conaway; Theresa J. Smith; Chung S. Yang πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 163 KB πŸ‘ 2 views

Natural and synthetic isothiocyanates (ITCs) are versatile chemopreventive agents in many animal systems. We have shown that phenethyl ITC (PEITC) and 6-phenylhexyl ITC (PHITC) are potent inhibitors against lung tumorigenesis induced by tobacco nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan

Methylation of RAS association domain fa
✍ Grote, Hans Juergen ;Schmiemann, Viola ;Geddert, Helene ;Bocking, Alfred ;Kappes πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 99 KB

## BACKGROUND. Promoter hypermethylation is an important mechanism for silencing tumor-suppressor genes in cancer and a promising tool for development of molecular biomarkers. This study aimed to determine the prevalence of RAS association domain family protein 1A (RASSF1A) promoter hypermethylati

ErbB4 increases the proliferation potent
✍ Alex Starr; Joel Greif; Akiva Vexler; Maia Ashkenazy-Voghera; Valery Gladesh; Ch πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 218 KB πŸ‘ 1 views

## Abstract Clinical and experimental data suggest that ErbB‐4, a member of the epidermal growth factor receptor family, may have a role in cancer progression and response to treatment. We found recently, using a retrospective clinical analysis, that expression of ErbB‐4 receptor is correlated with